Definium Therapeutics (DFTX) EBIT (2019 - 2026)
Definium Therapeutics (DFTX) reported EBIT of -$59.2 million for Q1 2026, down 84.15% year-over-year from -$373.6 million in Q1 2025, and down 24.47% on a QoQ basis from -$47.6 million in Q4 2025.
Definium Therapeutics (DFTX) has 8 years of EBIT data on file, last reported at -$59.2 million in Q1 2026.
- Quarterly EBIT fell 84.15% year-over-year to -$59.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$193.4 million (down 69.81% YoY) and the FY2025 annual result came in at -$166.3 million, down 60.04% from the prior year.
- EBIT slipped to -$59.2 million in Q1 2026 per DFTX's latest filing, from -$47.6 million in the prior quarter.
- Across five years, EBIT topped out at -$13.9 million in Q4 2022 and bottomed at -$59.2 million in Q1 2026.
- The 5-year median for EBIT is -$24.5 million (2024), against an average of -$28.8 million.
- Peak annual rise in EBIT reached 62.53% in 2022, while the deepest fall reached 124.6% in 2022.
- Tracing DFTX's EBIT over 5 years: stood at -$13.9 million in 2022, then sank by 59.75% to -$22.2 million in 2023, then slumped by 46.19% to -$32.5 million in 2024, then sank by 46.57% to -$47.6 million in 2025, then dropped by 24.47% to -$59.2 million in 2026.
- Per Business Quant, the three latest DFTX EBIT figures stand at -$59.2 million (Q1 2026), -$47.6 million (Q4 2025), and -$45.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -59.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -59.22 Mn |
| Dec 31, 2025 | -47.58 Mn |
| Sep 30, 2025 | -45.67 Mn |
| Jun 30, 2025 | -40.90 Mn |
| Mar 31, 2025 | -32.16 Mn |
| Dec 31, 2024 | -32.46 Mn |
| Sep 30, 2024 | -24.79 Mn |
| Jun 30, 2024 | -24.46 Mn |
| Mar 31, 2024 | -22.20 Mn |
| Dec 31, 2023 | -22.21 Mn |
| Sep 30, 2023 | -21.62 Mn |
| Jun 30, 2023 | -29.18 Mn |
| Mar 31, 2023 | -20.86 Mn |
| Dec 31, 2022 | -13.90 Mn |
| Sep 30, 2022 | -16.98 Mn |
| Jun 30, 2022 | -16.94 Mn |
| Mar 31, 2022 | -18.51 Mn |
| Dec 31, 2021 | 56.52 Mn |
| Sep 30, 2021 | -17.23 Mn |
| Jun 30, 2021 | -45.22 Mn |
| Mar 31, 2021 | -13.85 Mn |
| Dec 31, 2020 | 750,000.00 |
| Sep 30, 2020 | -8.68 Mn |
| Jun 30, 2020 | -5.72 Mn |
| Mar 31, 2020 | -7.03 Mn |
| Dec 31, 2019 | -10.73 Mn |